The 2017 numbers aren't kind to print-first publishers. Is this a blip in print's fortunes or the start of a long-predicted decline?
Whatever REDUCE-IT ultimately reveals (results from the completed study are expected in Q2 or Q3 2018), Salyer maintains Amarin has "a great story to tell, with or without the data."
Pharmacy benefit managers are increasingly measuring a patient's outcome in the context of adherence.
Second to market and dismissed as inferior to the competition, Sanofi's Aubagio seemed destined for lower-tier status. Here's how it overcame the initial obstacles and, five years later, become a potent market force
Two years after the first biosimilar approval in the U.S., biosimilars have yet to match sales forecasts. What is their path forward?
Biosimilars could save $54 billion in next decade; White House requests drug-pricing task force; FDA approves GSK shingle vaccine
The drugmaker eliminated its U.S. primary care, disease-focused endocrinology, and hospital chronic-care sales teams.
Amgen's Prolia tops the list, according to data compiled by EvaluatePharma.
Despite approvals of competing products from AbbVie, Merck, and Bristol-Myers Squibb, Gilead remains the market leader.
Pfizer's Prevnar tops the list, according to data compiled by EvaluatePharma.
He was diagnosed years ago with a handful of autoimmune conditions, treating them with drugs like Abbvie's Humira, which he helped commercialize.
Prescription rates dramatically decreased following the price hikes of Valeant's Isuprel and Nitropress in 47 hospitals.
What's holding back value-based pricing deals from moving beyond the pilot phase?
Five years ago, the notion of medical science liaisons as a guiding voice in the marketing mix was borderline preposterous. Now they're called upon early and often.
AbbVie's new HCV drug is cheaper than Gilead's Harvoni; Lilly's experimental migraine drugs beats placebo; Fitbit to launch smartwatch
The drugmaker is one step closer to a potential approval of its experimental cancer treatment.
Under siege from intense competition and the rise of value-based contracts, diabetes drugmakers look to outcomes data to stand out.
Medicare beneficiaries struggle to pay for COPD inhalers; Novartis partners with IBM Watson Health; Mylan hasn't lowered EpiPen prices
Drug prices, as you may have heard, are kind of high. But price growth has slowed after sharp spikes in 2014 and 2015.
Find data on patent expirations, new drug approvals, top therapeutic classes, and top-selling drugs.
A New York county sues drugmakers over opioid marketing; AstraZeneca files suit against GSK exec; Thermo Fisher acquires biologics firms
The top three most advertised brands in 2016 were Gilead Sciences' Harvoni, Eli Lilly's Trulicity, and J&J's Invokana.
Lilly to invest $850 million in the U.S.; President Trump gives GOP leaders ultimatum on healthcare bill; Pfizer, Merck KGaA receive FDA approval for Bavencio
Valeant added 250 primary care sales reps to promote its Salix portfolio.
Acorda CEO Ron Cohen applauded Marathon's move to pause the commercial activities for its new DMD drug.
Allergan said it would increase its investment in DTC after reporting slowing sales for its double-chin injection.
Thirty-percent of Keytruda's U.S. sales came from its lung-cancer indication.
Merck details price increases for its drugs; Trump's call to freeze federal hiring may not affect the FDA; Sanofi to settle vaccines-pricing lawsuit
Endo hires new head of U.S. branded pharma, and three other people moves for you to know about.
"In Australia, we are the healthcare industry," he says.